益血生胶囊联合DA化疗方案治疗急性髓系白血病临床研究  

Clinical Study on Yixuesheng Capsules Combined with DA Chemotherapy Regimen for Acute Myeloid Leukemia

作　　者：王娜[1] 秦玲[1] 刘珂[1] WANG Na;QIN Ling;LIU Ke

机构地区：[1]河南科技大学第一附属医院血液内科,河南洛阳471000

出　　处：《新中医》2020年第19期108-110,共3页New Chinese Medicine

摘　　要：目的:观察益血生胶囊联合DA化疗方案治疗急性髓系白血病(AML)的临床疗效。方法:选取140例AML患者,采用随机数字表法分为2组各70例。2组均给予止呕、护胃、水化等支持治疗,对照组采用常规DA化疗方案(柔红霉素+阿糖胞苷)治疗,观察组在对照组的基础上联用益血生胶囊治疗,连续治疗21 d。比较2组治疗前,治疗第7、14、21天白细胞计数、血小板计数、血红蛋白水平及治疗期间毒副反应发生情况。结果:治疗第7、14、21天,2组白细胞计数、血小板计数、血红蛋白水平均较治疗前降低,差异有统计学意义(P<0.05);观察组白细胞计数、血小板计数、血红蛋白水平高于同期对照组,差异有统计学意义(P<0.05)。观察组白细胞减少、血小板减少严重程度均低于对照组,差异有统计学意义(P<0.05);2组血红蛋白减少、胃肠道反应、肝损害情况比较,差异均无统计学意义(P>0.05)。结论:AML患者应用益血生胶囊联合DA化疗方案治疗,能够明显提升患者血常规指标水平,降低骨髓抑制严重程度。Objective:To observe the clinical effect of Yixuesheng capsules combined with DA chemotherapy regimen for acute myeloid leukemia(AML). Methods:A total of 140 cases of AML patients were divided into two groups according to the random number table method, 70 cases in each group. Both groups were given supportive treatments such as stopping vomiting,protecting the stomach,and hydration;the control group was given routine DA chemotherapy regimen including daunorubicin and cytarabine;the observation group was additionally treated with Yixuesheng capsules based on the treatment of the control group. Both groups were treated for 21 days. Before treatment as well as on the 7 th,14 thand 21 st days of treatment,white blood cell count,platelet count and the hemoglobin level as well as the incidence of toxic side effects during treatment were compared between the two groups. Results:On the 7 th,14 thand 21 stdays of treatment,the levels of white blood cells,platelets and hemoglobin in the two groups were decreased when compared with those before treatment,the difference being significant(P<0.05);the above three levels in the observation group were higher than those in the control group at the same period, the difference being significant(P<0.05). The severity of leukopenia and thrombocytopenia in the observation group was lower than that in the control group the difference being significant(P<0.05);when compared decreased hemoglobin, gastrointestinal responses and the liver impairment between the two groups,there was no significance in differences(P>0.05). Conclusion:AML patients treated with Yixuesheng capsules with DA chemotherapy regimen can significantly improve the levels of routine blood indexes,and reduce the severity of myelosuppression.

关 键 词：急性髓系白血病 益血生胶囊 柔红霉素 阿糖胞苷 骨髓抑制 

分 类 号：R733.71[医药卫生—肿瘤]